Vaccine: X : Impact Factor & More
eISSN: 2590-1362pISSN: 2590-1362
Open AccessShare this on:
Key Metrics
CiteScore 
3.9
SNIP
1.81
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Vaccine: X
Vaccine: X Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Tri-annual |
| Article Processing Charges | USD 2000 |
| Publication Time | 13 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Tri-annual |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Vaccine: X ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Vaccine: X
Immunogenicity of five Encapsidated DENV antigens supports their potential as a safe and protective subunit vaccine candidate
- 1 Dec 2025
- Vaccine: X
Effectiveness of vaccine dosing schedules for pneumococcal invasive disease in children: A systematic review and meta-analysis
- 1 Dec 2025
- Vaccine: X
COVID-19 and influenza vaccination among adults stably engaged in HIV care
- 1 Dec 2025
- Vaccine: X
Phase 2/3 open-label study on NVX-CoV-2601 (XBB.1.5) vaccine in previously COVID-19 mRNA vaccinated and vaccine-naive, SARS-CoV-2–seropositive participants: A 6-month follow-up
- 1 Dec 2025
- Vaccine: X
Effect of chronic disease rates and diagnoses on young adult pneumococcal vaccination status in the All of Us database
- 1 Dec 2025
- Vaccine: X
Primary caregivers' acceptance of gendered human papillomavirus (HPV) vaccination across The Gambia
- 1 Dec 2025
- Vaccine: X
Immunogenicity of five Encapsidated DENV antigens supports their potential as a safe and protective subunit vaccine candidate
- 1 Dec 2025
- Vaccine: X
Effectiveness of vaccine dosing schedules for pneumococcal invasive disease in children: A systematic review and meta-analysis
- 1 Dec 2025
- Vaccine: X
COVID-19 and influenza vaccination among adults stably engaged in HIV care
- 1 Dec 2025
- Vaccine: X
Phase 2/3 open-label study on NVX-CoV-2601 (XBB.1.5) vaccine in previously COVID-19 mRNA vaccinated and vaccine-naive, SARS-CoV-2–seropositive participants: A 6-month follow-up
- 1 Dec 2025
- Vaccine: X
Effect of chronic disease rates and diagnoses on young adult pneumococcal vaccination status in the All of Us database
- 1 Dec 2025
- Vaccine: X
Primary caregivers' acceptance of gendered human papillomavirus (HPV) vaccination across The Gambia
- 1 Dec 2025
- Vaccine: X
FAQs on Vaccine: X
How long has Vaccine: X been actively publishing? 
What is the publishing frequency of Vaccine: X?
How many articles did Vaccine: X publish last year?
What is the eISSN & pISSN for Vaccine: X?
What is Citescore for Vaccine: X?
What is SNIP score for Vaccine: X?
Who is the publisher of Vaccine: X?
